ArticleInfection and drug resistance2026
Time to Awaken a Forgotten Antibacterial Agent: A 10-year Nationwide Surveillance of Latamoxef Resistance in China Based on 46,716 Isolates and Establishment of Tentative Epidemiological Cut-Off Values.
Pan Chen, Erjia Zhang, Yingying Ma, Luying Xiong, Yunbo Chen, Ping Shen, Jinru Ji, Chaoqun Ying, Zhiying Liu, Yonghong Xiao
Abstract read
In one paragraphArticle in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Pan Chen *Peking Union Medical College & Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Research Units of Infectious Disease and Microecology, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.ORCID 0009-0009-1784-5425 Erjia Zhang *Department of Structure and Morphology, Jinan Microecological Biomedicine Shandong Laboratory, Jinan, People's Republic of China.
Yingying MaPeking Union Medical College & Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Research Units of Infectious Disease and Microecology, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Luying XiongState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Yunbo ChenState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.ORCID 0000-0002-5843-1386 Ping ShenState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Jinru JiState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.ORCID 0000-0003-1579-2250 Chaoqun YingState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.ORCID 0000-0001-8599-3838 Zhiying LiuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.ORCID 0000-0002-2060-1597 Yonghong XiaoDepartment of Structure and Morphology, Jinan Microecological Biomedicine Shandong Laboratory, Jinan, People's Republic of China.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Purpose: Latamoxef has been used to treat various bacterial infections. To provide data supporting the rational clinical use of latamoxef, bacterial resistance over 10 years was analyzed at multiple centers throughout China. The results were used to develop tentative epidemiological cut-off values (TECOFFs) for latamoxef. Methods: A total of 46,716 strains of common Results: The sensitivities of Conclusion: Latamoxef has good and stable in vitro antimicrobial activity against
Indexed as
antimicrobial resistanceepidemiological cut-off valueslatamoxefmoxalactamsurveillance
Identifiers
PMID41768377
PMCPMC12947658
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390